176 related articles for article (PubMed ID: 34055603)
1. Differential Predictors and Clinical Implications Associated With Long-Term Survivors in IDH Wildtype and Mutant Glioblastoma.
Jiang H; Yu K; Cui Y; Ren X; Li M; Zhang G; Yang C; Zhao X; Zhu Q; Lin S
Front Oncol; 2021; 11():632663. PubMed ID: 34055603
[TBL] [Abstract][Full Text] [Related]
2. Long-term survival in patients with IDH-wildtype glioblastoma: clinical and molecular characteristics.
Chehade G; Lawson TM; Lelotte J; Daoud L; Di Perri D; Whenham N; Duprez T; Tajeddine N; Tissir F; Raftopoulos C
Acta Neurochir (Wien); 2023 Apr; 165(4):1075-1085. PubMed ID: 36920664
[TBL] [Abstract][Full Text] [Related]
3. Molecular profiling of long-term IDH-wildtype glioblastoma survivors.
Burgenske DM; Yang J; Decker PA; Kollmeyer TM; Kosel ML; Mladek AC; Caron AA; Vaubel RA; Gupta SK; Kitange GJ; Sicotte H; Youland RS; Remonde D; Voss JS; Fritcher EGB; Kolsky KL; Ida CM; Meyer FB; Lachance DH; Parney IJ; Kipp BR; Giannini C; Sulman EP; Jenkins RB; Eckel-Passow JE; Sarkaria JN
Neuro Oncol; 2019 Nov; 21(11):1458-1469. PubMed ID: 31346613
[TBL] [Abstract][Full Text] [Related]
4. Differences in methylation profiles between long-term survivors and short-term survivors of IDH-wild-type glioblastoma.
van der Meulen M; Ramos RC; Voisin MR; Patil V; Wei Q; Singh O; Climans SA; Kalidindi N; Or R; Aldape K; Diamandis P; Munoz DG; Zadeh G; Mason WP
Neurooncol Adv; 2024; 6(1):vdae001. PubMed ID: 38312227
[TBL] [Abstract][Full Text] [Related]
5. Molecular features of glioblastomas in long-term survivors compared to short-term survivors-a matched-pair analysis.
Sommerlath VN; Buergy D; Etminan N; Brehmer S; Reuss D; Sarria GR; Guiot MC; Hänggi D; Wenz F; Petrecca K; Giordano FA
Radiat Oncol; 2022 Jan; 17(1):15. PubMed ID: 35073955
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive molecular characterization of long-term glioblastoma survivors.
Xu H; Chen X; Sun Y; Hu X; Zhang X; Wang Y; Tang Q; Zhu Q; Song K; Chen H; Sheng X; Yao Y; Zhuang D; Chen L; Mao Y; Qin Z
Cancer Lett; 2024 Jul; 593():216938. PubMed ID: 38734160
[TBL] [Abstract][Full Text] [Related]
7. Long-term survivors of glioblastoma: Tumor molecular, clinical, and imaging findings.
Briceno N; Vera E; Komlodi-Pasztor E; Abdullaev Z; Choi A; Grajkowska E; Kunst T; Levine J; Lindsley M; Fernandez K; Reyes J; Boris L; Burton E; Panzer M; Polskin L; Penas-Prado M; Pillai T; Theeler BJ; Wu J; Wall K; Papanicolau-Sengos A; Quezado M; Smirniotopoulos J; Aldape K; Armstrong TS; Gilbert MR
Neurooncol Adv; 2024; 6(1):vdae019. PubMed ID: 38420614
[TBL] [Abstract][Full Text] [Related]
8. Predictive value of MGMT promoter methylation on the survival of TMZ treated
Chai R; Li G; Liu Y; Zhang K; Zhao Z; Wu F; Chang Y; Pang B; Li J; Li Y; Jiang T; Wang Y
Cancer Biol Med; 2021 Feb; 18(1):272-282. PubMed ID: 33628600
[TBL] [Abstract][Full Text] [Related]
9.
Mittlmeier LM; Suchorska B; Ruf V; Holzgreve A; Brendel M; Herms J; Bartenstein P; Tonn JC; Unterrainer M; Albert NL
Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34202726
[TBL] [Abstract][Full Text] [Related]
10. An independently validated nomogram for isocitrate dehydrogenase-wild-type glioblastoma patient survival.
Gittleman H; Cioffi G; Chunduru P; Molinaro AM; Berger MS; Sloan AE; Barnholtz-Sloan JS
Neurooncol Adv; 2019; 1(1):vdz007. PubMed ID: 31608326
[TBL] [Abstract][Full Text] [Related]
11. Analysis of Factors Associated with Long-Term Survival in Patients with Glioblastoma.
Madhugiri VS; Moiyadi AV; Shetty P; Gupta T; Epari S; Jalali R; Subeikshanan V; Dutt A; Sasidharan GM; Roopesh Kumar VR; Shankar Ganesh CV; Ramesh AS; Sathia Prabhu A
World Neurosurg; 2021 May; 149():e758-e765. PubMed ID: 33540096
[TBL] [Abstract][Full Text] [Related]
12. O
Alassiri AH; Alkhaibary A; Al-Sarheed S; Alsufani F; Alharbi M; Alkhani A; Aloraidi A
Ann Saudi Med; 2019; 39(6):410-416. PubMed ID: 31804140
[TBL] [Abstract][Full Text] [Related]
13. Prognostic importance of temozolomide-induced neutropenia in glioblastoma, IDH-wildtype patients.
Saito T; Sugiyama K; Hama S; Yamasaki F; Takayasu T; Nosaka R; Muragaki Y; Kawamata T; Kurisu K
Neurosurg Rev; 2018 Apr; 41(2):621-628. PubMed ID: 28887717
[TBL] [Abstract][Full Text] [Related]
14. Long-term survival after glioblastoma resection: hope despite poor prognosis factors.
Costa E; Lawson TM; Lelotte J; Fomekong E; Vaz RG; Renard L; Whenham N; Raftopoulos C
J Neurosurg Sci; 2019 Jun; 63(3):251-257. PubMed ID: 29363298
[TBL] [Abstract][Full Text] [Related]
15. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
Li H; Li J; Cheng G; Zhang J; Li X
Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
[TBL] [Abstract][Full Text] [Related]
16. Arterial spin labeling perfusion-weighted imaging aids in prediction of molecular biomarkers and survival in glioblastomas.
Yoo RE; Yun TJ; Hwang I; Hong EK; Kang KM; Choi SH; Park CK; Won JK; Kim JH; Sohn CH
Eur Radiol; 2020 Feb; 30(2):1202-1211. PubMed ID: 31468161
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation and isocitrate dehydrogenase-1 (IDH-1) mutation in glioblastoma multiforme patients: A single-center experience in the Middle East region.
Ayoub Z; Geara F; Najjar M; Comair Y; Khoueiry-Zgheib N; Khoueiry P; Mahfouz R; Boulos FI; Kamar FG; Andraos T; Saadeh F; Kreidieh F; Abboud M; Skaf G; Assi HI
Clin Neurol Neurosurg; 2019 Jul; 182():92-97. PubMed ID: 31108342
[TBL] [Abstract][Full Text] [Related]
18. Topographical Mapping of 436 Newly Diagnosed IDH Wildtype Glioblastoma With vs. Without MGMT Promoter Methylation.
Incekara F; van der Voort SR; Dubbink HJ; Atmodimedjo PN; Nandoe Tewarie R; Lycklama G; Vincent AJPE; Kros JM; Klein S; van den Bent M; Smits M
Front Oncol; 2020; 10():596. PubMed ID: 32477929
[No Abstract] [Full Text] [Related]
19. Comparative analysis of deeply phenotyped GBM cohorts of 'short-term' and 'long-term' survivors.
Biswas A; Salvucci M; Connor K; Düssmann H; Carberry S; Fichtner M; King E; Murphy B; O'Farrell AC; Cryan J; Beausang A; Heffernan J; Cremona M; Hennessy BT; Clerkin J; Sweeney KJ; MacNally S; Brett F; O'Halloran P; Bacon O; Furney S; Verreault M; Quissac E; Bielle F; Ahmed MH; Idbaih A; Leenstra S; Ntafoulis I; Fabro F; Lamfers M; Golebiewska A; Hertel F; Niclou SP; Yen RTC; Kremer A; Dilcan G; Lodi F; Arijs I; Lambrechts D; Purushothama MK; Kel A; Byrne AT; Prehn JHM
J Neurooncol; 2023 Jun; 163(2):327-338. PubMed ID: 37237151
[TBL] [Abstract][Full Text] [Related]
20. The involvement of brain regions associated with lower KPS and shorter survival time predicts a poor prognosis in glioma.
Bao H; Wang H; Sun Q; Wang Y; Liu H; Liang P; Lv Z
Front Neurol; 2023; 14():1264322. PubMed ID: 38111796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
